Macroaggregate formation in optimal additive red cells

White thrombus formation in blood tubing lines in a chronic hemodialysis unit

BACKGROUND AND OBJECTIVES

Previous reports have described white particulate matter in banked blood components, but no prior public reports describe such matter in blood tubing during the course of routine in-center hemodialysis. This report describes the events, investigations, and preliminary conclusions associated with the spontaneous formation of adherent white thrombus in the venous and arterial blood lines during routine in-center hemodialysis treatments. Design setting, participants, & measurements: This investigation occurred at the Portland Veterans Administration Medical Center (PVAMC) Hemodialysis Unit from October 2006 through April 2007. Sixty-eight variables regarding demographics, medical history and dialysis treatments were collected on our 34 chronic hemodialysis outpatients.

RESULTS

Over a 5-wk interval, 62% (21 of 34) of the chronic hemodialysis patients unexpectedly developed a white precipitate adhering to the lumenal surface of their dialysis blood tubing, with 73 of 580 chronic dialysis treatments exhibiting the phenomenon. Microscopic and biochemical analyses were consistent with white thrombus, formed by an aggregation of platelets and fibrin. An alert was issued and other in-center hemodialysis units noted similar findings. This was remedied by the removal of specific tubing.

CONCLUSIONS

Both patient-specific and tubing-specific factors may have been operative. Although patient safety was not adversely affected, assessment of clinical and manufacturing variables potentially affecting platelet activation is warranted.

White particulate matter found in blood collection bags consist of platelets and leukocytes

BACKGROUND

In late January 2003, some blood centers and hospitals throughout the US voluntarily sus-pended the use of some RBC and plasma units for trans-fusion due to the presence of unknown white particulate matter (WPM) in these units. To better understand the WPM phenomena, a number of technologies were used to establish the nature of the particulates observed in Terumo Collection sets.

STUDY DESIGN AND METHODS

All AS-5 nonleuko-reduced RBCs and plasma units were visually inspected for WPM by placing the bags on a flat counter, undisturbed, for approximately 10 minutes and then perform-ing a visual examination for particles. Particles were isolated and placed on microscope slides or in plastic tubes for further analysis. Electron microscopy, bright field microscopy, differential interference contrast microscopy, infrared spectroscopy, and flow cytometry procedures were performed to establish the nature of the particulate matter. In addition, leukoreduction filters and blood transfusion sets were used on RBCs units with WPM.

RESULTS

The particles were mostly composed of PLTs and WBCs, and fragments of these cells. All macroscopic WPM was removed from RBCs with leukoeduction and transfusion filters.

CONCLUSIONS

WPM originated from PLTs and WBCs. Foreign matter (e.g., plastic) was not observed in any of the units. Leukoreduction and transfusion filters can be used to remove macroscopic WPM.

Particulate matter phenomenon: adverse event data and the effect of leukofiltration

BACKGROUND

In February 2002, a multiorganizational task force investigated blood center reports of unusual particulate matter (PM) visible in packed red blood cells (RBC). A cohort study assessed increase in adverse events (AEs) related to this phenomenon, as well as the effect of post-leukofiltration (LF) on PM.

METHODS

Two blood centers assessed AEs in patients transfused with RBCs having visible PM (classified as normal by-products of RBC preparation), PM RBCs subsequently LF, or RBCs without visible PM, and the effect of LF on PM removal.

RESULTS

There was no difference in AEs in patients transfused with PM RBCs with or without LF compared to patients transfused with RBCs without visible PM. Subsequently filtered PM RBCs had acceptable residual WBC counts and median platelet removal of 92%.

CONCLUSION

Transfusion of RBCs with visible PM or RBCs subsequently LF does not appear to increase the risk of an AE. LF use on PM RBCs results in the PM removal without adversely affecting filter performance. The lack of evidence of an increase in AE reports does not mean that there is no effect, and there may be a baseline AE rate attributable to PM which has not been thoroughly researched.

White particulate matter: report of the ad hoc industry review group

BACKGROUND

In January 2003, blood center personnel in the American Red Cross, Southern Region in Atlanta, noticed whitish particulate material (WPM) that had not been observed previously in several units of red blood cells (RBCs). An expert panel was formed to evaluate studies of the material and make appropriate recommendations

STUDY DESIGN AND METHODS

The expert panel reviewed information provided by several investigations and organizations. This included: background information, and experiences relating to WPM; WPM composition; factors promoting WPM formation; risk of WPM (if any) to patients; and recommendations to prevent future occurrences.

RESULTS

WPM is derived from blood. No data suggest that external contamination or collection set components contribute to WPM development. A major constituent of WPM is platelets (PLTs). WPM is most commonly observed in RBCs that have been subjected to a hard spin without PLT separation. WPM is rarely, if ever, observed in RBCs that have been subjected to leukoreduction.

CONCLUSIONS

(1) WPM is not new, can be prevented, and can be removed. (2) WPM contains PLTs, white blood cells, fibrin, and cellular debris. (3) Changes in blood handling are not necessary. (4) WPM may be more frequent when higher g forces are used in component preparation. (5) Enhanced visual inspection of blood components need not be continued. (6) It appears that WPM may not form in RBC collected using automated devices. (7) WPM did not pose a risk to patients but should be avoided.

Description and investigation of white particulate matter in additive solution-1 red blood cell units

BACKGROUND

In January 2003, "white particulate matter" (WPM) was transiently observed in red blood cell (RBC) units collected predominately in the southeastern US. In this report, these events, their chronology, pertinent observations and investigations, and summaries and conclusions associated with WPM during the 2-week observation period are described.

CHRONOLOGY AND INVESTIGATIONS

On January 27, 2003, WPM was first identified in RBCs; by January 31, 2003, 110 RBC units containing WPM had been identified. Elective surgeries were postponed. Approximately 400 RBC units containing WPM were inspected in the blood center and characterized into four types: I, II, III, and IV. A variety of preparations of aspirated WPM were made, including light and electron microscopic sections.

RESULTS AND CONCLUSIONS

The rate of WPM-containing units was 1.67 percent (1 in 60 units), whereas the background incidence was less than 0.25 percent. Investigations revealed that WPM was composed of activated and nonactivated platelets (PLTs); no toxins, infectious agents, or agents of bioterrorism were identified. WPM correlated with certain variables studied, including PLT-rich components that had been centrifuged with a "hard spin" before leukoreduction and manufactured in one vendor's collection sets. Because the increased rate of appearance of WPM was a transient phenomenon, it is not clear whether this is a newly noticed or a new and different phenomenon from "aggregates" observed in the past.

Filters in anaesthesia and intensive care

The use of various types of filters in anaesthesia and intensive care seems ubiquitous, yet authentication of the practice is scarce and controversies abound. This review examines evidence for the practice of using filters with blood and blood product transfusion (standard blood filter, microfilter, leucocyte depletion filter), infusion of fluids, breathing systems, epidural catheters, and at less common sites such as with Entonox inhalation in non-intubated patients, forced air convection warmers, and air-conditioning systems. For most filters, the literature failed to support routine usage, despite this seemingly being popular and innocuous. The controversies, as well as guidelines if available, for each type of filter, are discussed. The review aims to rationalize the place of various filters in the anaesthesia and intensive care environment.

Bradykinin generation in RC-MAP during storage at 4 degrees C and leukocyte removal filtration

We investigated contact system activation in red cell concentrate in mannitol-adenine-phosphate (MAP) solution (RC-MAP) during storage and leukocyte removal filtration. The contact system activation was assessed in terms of bradykinin (BK) generation. The BK level in the RC-MAP transiently but significantly (p < 0.05) increased at 7 to 14 days of storage. Moreover, the BK level in 21-day-stored RC-MAP was approximately 10 times higher than that in other blood components. The BK level in mannitol-containing MAP solutions, but not that in mannitol-free MAP solution, saline or whole blood, increased during storage. The plasma angiotensin-converting enzyme (ACE) activity decreased significantly only in mannitol-containing MAP solutions. These findings suggest that mannitol plays an essential role in the increase in BK level in RC-MAP. Furthermore, the BK level in RC-MAP increased 10 minutes after the start of filtration through a negatively charged filter, either a BPF-4 or an RN-40, and reached a maximum of 6,000 pg/ml. Hypotensive reactions are rare in RC-MAP transfusion in comparison to their incidence in platelet concentrate (PC) transfusion in spite of the higher BK level in RC-MAP than in PC. Therefore, BK generation in various blood components is not likely to be the main cause of hypotensive reactions. However, the level of BK in RC-MAP is sufficiently high to cause site pain. Further investigation on the clinical significance of a high BK level in blood components is necessary.

Blood product costing: relationship to price and clinical efficacy

Detailed information is provided about primary product costing and price issues as they affect transfusion manufacturing practice and clinical transfusion practice. Product price is shown to have a crucial influence upon clinical practice and associated research. By focusing particularly upon cost-benefit analysis of blood product transfusion therapy a substantive conclusion is drawn that price should equal the associated manufacturing cost. Clinical outcome studies relate clinical efficacy to the manufacturing specification of the product, which should therefore determine the product cost. Thus, the true manufacturing cost is the sum of all the process activity costs that create the final product specification, e.g. red cell number+volume reduction+leucocyte reduction+microbiological safety, for processed red cells. Sometimes different product specifications may compete for a single activity cost, e.g. one-spin processing achieves volume reduction and leucocyte reduction for processed red cells but also plasma removal for protein fractionation. A method for understanding the relative clinical importance of different products is described, which guides the cost allocation process. Furthermore, for some products there is uncertainty about the clinical benefits of some components of the specification, e.g. leucocyte load and immunomodulation, and a method is described for ranking this quality-uncertainty level objectively. The optimal costing model must ensure that the product with the highest uncertainty ranking is assured a high degree of cost stability. These concepts prepare the way for a Quality Associated Costing model for blood products that correlates with clinical efficacy.

Electrical impedance alterations of red blood cells during storage

The electrical impedance of blood is determined mainly by the resistance of the plasma (Rp), resistance of the red cell interior fluid (Ri), and capacitance of the cell membranes (Cm). These parameters were measured on 10 stored blood samples consecutively during 4 or 5 weeks of storage at 4 degrees C, once every week. Compared to the values of fresh samples, a statistically significant decrease in Rp was found mainly during the first week of storage, Ri did not decrease significantly until after 3 weeks, whereas Cm decreased progressively with time. These alterations can be explained by known red cell lesions during storage. The results indicate that electrical impedance measurements might be useful for monitoring red cell ageing and assessing the quality of stored red blood cells.

The role of blood microfilters in clinical practice

Blood filters have been available since the 1930s. In this review we evaluate the role of microaggregate filters (MF) in certain transfusion complications, namely non-haemolytic febrile transfusion reactions (NHFTR), pulmonary injury, thrombocytopenia, fibronectin depletion and histamine release. We review the latest generation of leucocyte depleting filters and discuss their role in preventing alloimmunisation, immunosuppression and CMV transmission. Finally, we provide a rationale for the role of blood microfiltration in the present day practice of intensive care medicine.

The bottom and top system: a new technique for blood component preparation and storage

A new, automated technique for the preparation of blood components is described. A system of 3 or 4 integrally connected plastic containers (Optipac) is handled by a new type of extractor (Optipress). The container in which the blood is collected has an outlet at the top and another at the bottom. After normal centrifugation to obtain separation of the blood components, these are squeezed out from the top and bottom simultaneously under control of a photocell. The primary separation step results in three components: a leukocyte-poor red-cell suspension in SAGM medium, CPD plasma, and a buffy-coat preparation. The system has been tested in two laboratories (lab A and lab B). A 'heavy-spin' centrifugation to obtain a maximum yield of cell-poor plasma gave the best removal of leukocytes from the red cells; the remaining leukocyte content was 0.46 +/- 0.25 (lab A) and 0.5 +/- 0.4 (lab B) x 10(9)/red-cell unit. Platelet concentrates can be prepared either the normal way via platelet-rich plasma or from buffy coat. Red-cell 24-hour autologous posttransfusion survival using labeling with 51Cr was 87.5 +/- 4.1% (lab A) after 35 days, and 84.2 +/- 4.2% (lab A) and 77.5 +/- 1.5% (lab B) after 42 days. Red-cell morphology and fluidity compared favorably to previous studies using the same additive solution in traditional plastic-bag systems. The total adenine nucleotide concentration was maintained normal for 42 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Red cell membrane changes during storage

A great deal is known about the red cell membrane and its abnormalities in various pathologic states. During red cell storage there is a progressive development of spheroechniocytosis with eventual production of irreversibly nondeformable red cells. The loss of membrane function is most likely related to some abnormality in maintenance of the cytoskeleton of the red cell. These changes appear to occur independent of ATP levels. Despite the increasing knowledge of the structure and function of the red cell membrane very little as yet is known about the specific abnormality in the red cell membrane that occurs during storage in the blood bank. Recent evidence for abnormal spectrin-actin interaction and abnormal spectrin oxidation has been the most promising. Areas of interest for research include studies of the specific mechanisms by which the plasticizer DEHP interacts with the membrane, specific definition of the molecular defect in membrane proteins that occurs during storage, and means to prevent these. If such deterioration and membrane stiffening could be prevented then the quality of the red cells that are transfused would be improved both in their function and ability to survive in the microcirculation. A final need, while not of specific value to the red cell itself, is the development of media and additives that will allow for increased plasma and Factor VIII yields, one of the driving forces in the blood transfusion system.

Flow properties of modified packed red cells

We investigated free gravitational blood flow of modified packed red cells. Variables affecting free flow included final haematocrit, duration of blood storage at 4-6 degrees C and the centrifugal force required in preparation of this blood component. Irrespective of the duration of storage, free blood flow of modified packed red cells was not different from whole blood, provided the haematocrit did not exceed 0.63.

Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant

The effect of replacing a standard citrate anticoagulant with one containing half the amount of citrate on the in vitro properties of components prepared from blood donations was investigated. This resulted in a significant improvement in factor VIII stability such that there was little loss during overnight storage, and this was reflected in the factor VIII yield in cryoprecipitate. The quality of cellular components in red cell units stored up to 35 days or platelet concentrates stored up to 7 days was not adversely affected. Although initial levels were similar to those in standard anticoagulant, the extent of fibrinopeptide A generation and complement C3 breakdown in red cell units stored for 35 days in half-strength citrate was somewhat increased.